Realheart's development plan 2021
Despite the pandemic, during 2020 Realheart has achieved most of its previously communicated goals and milestones in the work of commercializing its artificial heart. In 2021, the company intends to focus on product development, animal studies and progress towards FDA requirements.In 2020, Realheart's development work focused on the areas of product development, supplier and collaboration agreements, as well as working towards FDA requirements. In light of the Corona pandemic, the company has succeeded in achieving most of the set goals. The new partner Berlin Heart - Europe's largest heart
Investments to fund development into the world's leading D2C brand house / Human-to-human model at the forefront at The Stryze
The Stryze Group offers consumers high-quality direct-to-consumer (D2C) brands at fair prices across multiple platforms – anywhere, anytime. Now, Upper90, Alstin Capital and another German institutional investor are investing up to 100 million US dollars in the company. In addition to organic growth of own brands, this will also be used to finance acquisitions. "We are not financially driven, but interested in brands, their development and the people behind them,"